Chemotherapy Research and Practice / 2012 / Article / Tab 1

Review Article

EGFR Monoclonal Antibodies in the Treatment of Squamous Cell Carcinoma of the Head and Neck: A View beyond Cetuximab

Table 1

EGFR-targeting monoclonal antibodies (MoAb) in development for SCCHN treatment.

Agent (mechanism)Trial descriptionIdentifier number (status)

Necitumumab (fully human IgG1 MoAb) Phase I trial of IMC-11F8 in patients with advanced solid tumorsNCT01088464
Phase I trial of IMC-11F8 in patients with tumors who have not responded to standard therapy NCT00801177

Zalutumumab (fully human IgG1k MoAb)Phase I/II: Zalutumumab pharmacokinetics (PK) in squamous cell carcinoma of the head and neck (SCCHN) NCT01054625
Phase 3: DAHANCA 19: The importance of the EGFr-inhibitor zalutumumab for the outcome after curative radiotherapy for HNSCC NCT00496652
Phase I/II: An open, single-dose escalation study followed by a multiple dose extension of Anti-EGF receptor human MoAb (zalutumumab) in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN) NCT00093041

Panitumumab (fully human IgG2 MoAb)Phase II: PRISM (panitumumab regimen in second-line monotherapy of head and neck cancer)
Phase II: Radiotherapy plus panitumumab compared to chemoradiotherapy with unresected, locally advanced SCCHN NCT00547157
Phase II: Study of addition of panitumumab to chemoradiation therapy in subjects with locally advanced head and neck cancer NCT00500760
Phase I: Study panitumumab plus chemotherapy and induction chemotherapy in patients with locally advanced squamous cell cancer of the head and neck NCT00513383
Phase II: Trial of postoperative radiation, cisplatin, and panitumumab in locally advanced head and neck cancer NCT00798655
Phase II: PARTNER: panitumumab added to regimen for treatment of head and neck cancer evaluation of response NCT00454779

Phase III: Radiation therapy and cisplatin or Panitumumab in treating patients with locally advanced stage III or IV head and neck cancerNCT00820248
Phase II: Randomized pharmacokinetic trial of chemotherapy with or without panitumumab in patients with R/M SCCHN NCT00756444 (Active, not recruiting)
Phase II: Identification of gene expression signature for panitumumab sensitivity in untreated locally advanced SCCHN (TOP 0901) NCT01305772 (Recruiting)
Nimotuzumab (humanized IgG1 MoAb)Phase II: Nimotuzumab in combination with TPF (cisplatin, fluorouracil, docetaxel) for head and neck squamous cell carcinoma NCT01425736 (Recruiting)
Phase III: nimotuzumab in combination with chemoradiation for nasopharyngeal cancer NCT01074021 (Recruiting)
Phase II: Induction chemotherapy with nimotuzumab in locally advanced head and neck squamous cell carcinoma (HNSCC) NCT00910117 (Completed)
Phase II: Safety and efficacy of target therapy combined with radiotherapy to treat senile locally advanced SCCHN NCT01393184 (Recruiting)
Phase II: Safety and efficacy of nimotuzumab plus neoadjuvant and concurrent chemoradiotherapy to treat oropharynx and hypopharynx cancer NCT01516996 (Recruiting)
Phase III: Study of Post-Op adjuvant concurrent Chemo-RT with or without nimotuzumab for head and neck cancer NCT00957086 (Recruiting)
Phase II: Study comparing radiation therapy alone and radiation therapy and nimotuzumab for treatment of head and neck cancer NCT01345084 (Not yet open for recruitment)